Not provided
Not provided
Not provided
Not provided
Not provided
Study terminated for administrative reasons.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Flibanserin 100 mg | Experimental | Flibanserin 100 mg administered at bedtime |
|
| Placebo | Placebo Comparator | This is the matched placebo which will be administered two tablets daily at bedtime. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Flibanserin | Drug | Flibanserin 100mg administered at bedtime for 24 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Number of Satisfying Sexual Events | The change from baseline in the number of SSE's as measured by the eDiary. The calculation of Satisfying Sexual Event (SSEs) will be standardized to a 28-day period according to the below formula: Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered). "Satisfying" means gratifying, fulfilling, satisfactory, and/or successful for the patient. The partner's satisfaction is not the subject of this question. | baseline to 24 weeks |
| Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire Domain | The Female Sexual Function Index (FSFI) is a brief, multidimensional, self-administered questionnaire for assessing key domains of sexual function in women. The scale consists of 19 items that assess sexual function over the past four weeks and yields scores in six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The two items in the desire domain are scored from 1 to 5 (1 is lowest level of desire and 5 is the highest level of desire). The raw scores of the two items are added together and then multiplied by the domain factor of 0.6. Thus, the score of the desire domain ranges from 1.2 (lowest level of desire) to 6.0 (highest level of desire). For the entire instrument, each of the six domains contributes a maximum of 6 points to the total. Scores on the full scale range from a minimum of 2 to a maximum of 36. | baseline to 24 weeks |
Not provided
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 511.156.01059 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | United States | |||
| 511.156.01084 Boehringer Ingelheim Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28583342 | Derived | Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA. Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study. J Sex Med. 2017 Jun;14(6):834-842. doi: 10.1016/j.jsxm.2017.03.258. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Flibanserin 100 mg | Flibanserin 100 mg administered at bedtime Flibanserin: Flibanserin 100mg administered at bedtime for 24 weeks |
| FG001 | Placebo | This is the matched placebo which will be administered two tablets daily at bedtime. Placebo: This is the matched placebo which will be administered two tablets daily at bedtime. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
This is the matched placebo which will be administered two tablets daily at bedtime. |
|
| Tucson |
| Arizona |
| United States |
| 511.156.01053 Boehringer Ingelheim Investigational Site | Tuscon | Arizona | United States |
| 511.156.01069 Boehringer Ingelheim Investigational Site | Tuscon | Arizona | United States |
| 511.156.01063 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | United States |
| 511.156.01076 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | United States |
| 511.156.01039 Boehringer Ingelheim Investigational Site | Anaheim | California | United States |
| 511.156.01070 Boehringer Ingelheim Investigational Site | Berkeley | California | United States |
| 511.156.01075 Boehringer Ingelheim Investigational Site | La Mesa | California | United States |
| 511.156.01087 Boehringer Ingelheim Investigational Site | Los Angeles | California | United States |
| 511.156.01064 Boehringer Ingelheim Investigational Site | Newport Beach | California | United States |
| 511.156.01016 Boehringer Ingelheim Investigational Site | Oceanside | California | United States |
| 511.156.01007 Boehringer Ingelheim Investigational Site | San Diego | California | United States |
| 511.156.01038 Boehringer Ingelheim Investigational Site | San Diego | California | United States |
| 511.156.01067 Boehringer Ingelheim Investigational Site | Colorado Springs | Colorado | United States |
| 511.156.01036 Boehringer Ingelheim Investigational Site | Denver | Colorado | United States |
| 511.156.01092 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | United States |
| 511.156.01027 Boehringer Ingelheim Investigational Site | New London | Connecticut | United States |
| 511.156.01022 Boehringer Ingelheim Investigational Site | Coral Gables | Florida | United States |
| 511.156.01042 Boehringer Ingelheim Investigational Site | DeLand | Florida | United States |
| 511.156.01047 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | United States |
| 511.156.01051 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | United States |
| 511.156.01011 Boehringer Ingelheim Investigational Site | Gainseville | Florida | United States |
| 511.156.01078 Boehringer Ingelheim Investigational Site | Lake Worth | Florida | United States |
| 511.156.01095 Boehringer Ingelheim Investigational Site | Orlando | Florida | United States |
| 511.156.01046 Boehringer Ingelheim Investigational Site | Plantation | Florida | United States |
| 511.156.01056 Boehringer Ingelheim Investigational Site | Columbus | Georgia | United States |
| 511.156.01045 Boehringer Ingelheim Investigational Site | Marietta | Georgia | United States |
| 511.156.01021 Boehringer Ingelheim Investigational Site | Roswell | Georgia | United States |
| 511.156.01081 Boehringer Ingelheim Investigational Site | Savannah | Georgia | United States |
| 511.156.01066 Boehringer Ingelheim Investigational Site | Boise | Idaho | United States |
| 511.156.01025 Boehringer Ingelheim Investigational Site | Chicago | Illinois | United States |
| 511.156.01028 Boehringer Ingelheim Investigational Site | Chicago | Illinois | United States |
| 511.156.01089 Boehringer Ingelheim Investigational Site | South Bend | Indiana | United States |
| 511.156.01010 Boehringer Ingelheim Investigational Site | Wichita | Kansas | United States |
| 511.156.01008 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | United States |
| 511.156.01034 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | United States |
| 511.156.01012 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | United States |
| 511.156.01074 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | United States |
| 511.156.01079 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | United States |
| 511.156.01080 Boehringer Ingelheim Investigational Site | Haverhill | Massachusetts | United States |
| 511.156.01006 Boehringer Ingelheim Investigational Site | Detroit | Michigan | United States |
| 511.156.01086 Boehringer Ingelheim Investigational Site | Paw Paw | Michigan | United States |
| 511.156.01005 Boehringer Ingelheim Investigational Site | Chaska | Minnesota | United States |
| 511.156.01013 Boehringer Ingelheim Investigational Site | Olive Branch | Mississippi | United States |
| 511.156.01088 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | United States |
| 511.156.01001 Boehringer Ingelheim Investigational Site | New Brunswick | New Jersey | United States |
| 511.156.01055 Boehringer Ingelheim Investigational Site | Plainsboro | New Jersey | United States |
| 511.156.01037 Boehringer Ingelheim Investigational Site | Poughkeepsie | New York | United States |
| 511.156.01031 Boehringer Ingelheim Investigational Site | Purchase | New York | United States |
| 511.156.01009 Boehringer Ingelheim Investigational Site | The Bronx | New York | United States |
| 511.156.01024 Boehringer Ingelheim Investigational Site | Cary | North Carolina | United States |
| 511.156.01065 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | United States |
| 511.156.01029 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | United States |
| 511.156.01002 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | United States |
| 511.156.01040 Boehringer Ingelheim Investigational Site | Statesville | North Carolina | United States |
| 511.156.01026 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | United States |
| 511.156.01093 Boehringer Ingelheim Investigational Site | Bismarck | North Dakota | United States |
| 511.156.01052 Boehringer Ingelheim Investigational Site | Fargo | North Dakota | United States |
| 511.156.01017 Boehringer Ingelheim Investigational Site | Beachwood | Ohio | United States |
| 511.156.01032 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | United States |
| 511.156.01033 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | United States |
| 511.156.01068 Boehringer Ingelheim Investigational Site | Englewood | Ohio | United States |
| 511.156.01077 Boehringer Ingelheim Investigational Site | Ashland | Oregon | United States |
| 511.156.01072 Boehringer Ingelheim Investigational Site | Medford | Oregon | United States |
| 511.156.01082 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | United States |
| 511.156.01094 Boehringer Ingelheim Investigational Site | West Reading | Pennsylvania | United States |
| 511.156.01083 Boehringer Ingelheim Investigational Site | Warwick | Rhode Island | United States |
| 511.156.01048 Boehringer Ingelheim Investigational Site | Anderson | South Carolina | United States |
| 511.156.01058 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | United States |
| 511.156.01085 Boehringer Ingelheim Investigational Site | Watertown | South Dakota | United States |
| 511.156.01073 Boehringer Ingelheim Investigational Site | Bristol | Tennessee | United States |
| 511.156.01041 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | United States |
| 511.156.01035 Boehringer Ingelheim Investigational Site | Germantown | Tennessee | United States |
| 511.156.01091 Boehringer Ingelheim Investigational Site | Jackson | Tennessee | United States |
| 511.156.01060 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | United States |
| 511.156.01003 Boehringer Ingelheim Investigational Site | Austin | Texas | United States |
| 511.156.01054 Boehringer Ingelheim Investigational Site | Dallas | Texas | United States |
| 511.156.01050 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | United States |
| 511.156.01014 Boehringer Ingelheim Investigational Site | Houston | Texas | United States |
| 511.156.01049 Boehringer Ingelheim Investigational Site | San Antonio | Texas | United States |
| 511.156.01015 Boehringer Ingelheim Investigational Site | Richmond | Virginia | United States |
| 511.156.01090 Boehringer Ingelheim Investigational Site | Richmond | Virginia | United States |
| 511.156.01020 Boehringer Ingelheim Investigational Site | Seattle | Washington | United States |
| 511.156.02004 Boehringer Ingelheim Investigational Site | Calgary | Alberta | Canada |
| 511.156.02010 Boehringer Ingelheim Investigational Site | Coquitlam | British Columbia | Canada |
| 511.156.02009 Boehringer Ingelheim Investigational Site | Vancouver | British Columbia | Canada |
| 511.156.02014 Boehringer Ingelheim Investigational Site | Victoria | British Columbia | Canada |
| 511.156.02012 Boehringer Ingelheim Investigational Site | Winnipeg | Manitoba | Canada |
| 511.156.02017 Boehringer Ingelheim Investigational Site | Winnipeg | Manitoba | Canada |
| 511.156.02007 Boehringer Ingelheim Investigational Site | Woodstock | New Brunswick | Canada |
| 511.156.02008 Boehringer Ingelheim Investigational Site | Mount Pearl | Newfoundland and Labrador | Canada |
| 511.156.02001 Boehringer Ingelheim Investigational Site | Halifax | Nova Scotia | Canada |
| 511.156.02013 Boehringer Ingelheim Investigational Site | Barrie | Ontario | Canada |
| 511.156.02006 Boehringer Ingelheim Investigational Site | Burlington | Ontario | Canada |
| 511.156.02005 Boehringer Ingelheim Investigational Site | Ottawa | Ontario | Canada |
| 511.156.02016 Boehringer Ingelheim Investigational Site | Toronto | Ontario | Canada |
| 511.156.02002 Boehringer Ingelheim Investigational Site | Québec | Quebec | Canada |
| 511.156.02015 Boehringer Ingelheim Investigational Site | Sherbrooke | Quebec | Canada |
| 511.156.02003 Boehringer Ingelheim Investigational Site | Saskatoon | Saskatchewan | Canada |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Flibanserin 100 mg | Flibanserin 100 mg administered at bedtime Flibanserin: Flibanserin 100mg administered at bedtime for 24 weeks |
| BG001 | Placebo | This is the matched placebo which will be administered two tablets daily at bedtime. Placebo: This is the matched placebo which will be administered two tablets daily at bedtime. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number | participants |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in the Number of Satisfying Sexual Events | The change from baseline in the number of SSE's as measured by the eDiary. The calculation of Satisfying Sexual Event (SSEs) will be standardized to a 28-day period according to the below formula: Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered). "Satisfying" means gratifying, fulfilling, satisfactory, and/or successful for the patient. The partner's satisfaction is not the subject of this question. | The full analysis set (FAS), consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, had at least one baseline value of either one of the co-primary endpoints or key secondary endpoint, and had usable data. | Posted | Mean | Standard Deviation | SSEs/month | baseline to 24 weeks |
|
|
| ||||||||||||||||||||||||||||
| Primary | Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire Domain | The Female Sexual Function Index (FSFI) is a brief, multidimensional, self-administered questionnaire for assessing key domains of sexual function in women. The scale consists of 19 items that assess sexual function over the past four weeks and yields scores in six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The two items in the desire domain are scored from 1 to 5 (1 is lowest level of desire and 5 is the highest level of desire). The raw scores of the two items are added together and then multiplied by the domain factor of 0.6. Thus, the score of the desire domain ranges from 1.2 (lowest level of desire) to 6.0 (highest level of desire). For the entire instrument, each of the six domains contributes a maximum of 6 points to the total. Scores on the full scale range from a minimum of 2 to a maximum of 36. | The full analysis set (FAS), consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, had at least one baseline value of either one of the co-primary endpoints or key secondary endpoint, and had usable data. | Posted | Least Squares Mean | Standard Error | units on a scale | baseline to 24 weeks |
|
Not provided
Among the 372 randomized patients, 369 took at least one dose of study medication and had at least one post-dose on-treatment safety assessment. These patients were included in the treated set that was analyzed for safety.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Flibanserin 100 mg | Flibanserin 100 mg administered at bedtime Flibanserin: Flibanserin 100mg administered at bedtime for 24 weeks | 6 | 376 | 118 | 376 | ||
| EG001 | Placebo | This is the matched placebo which will be administered two tablets daily at bedtime. Placebo: This is the matched placebo which will be administered two tablets daily at bedtime. | 4 | 369 | 74 | 369 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diverticulitis | Infections and infestations | Systematic Assessment |
| ||
| Gastroenteritis viral | Infections and infestations | Systematic Assessment |
| ||
| Breast Cancer in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Transient ischemic event | Nervous system disorders | Systematic Assessment |
| ||
| Liver function test abnormal | Investigations | Systematic Assessment |
| ||
| Fall | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| hip fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| meniscus lesion | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| road traffic accident | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| tibia fracture | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Insomnia | Psychiatric disorders | Systematic Assessment |
| ||
| somnolence | Nervous system disorders | Systematic Assessment |
| ||
| headache | Nervous system disorders | Systematic Assessment |
| ||
| dizziness | Nervous system disorders | Systematic Assessment |
| ||
| nausea | Gastrointestinal disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Krista Barbour, Ph.D. | Sprout Pharmaceuticals | 9198820850 | kbarbour@sproutpharma.com |
| ID | Term |
|---|---|
| D020018 | Sexual Dysfunctions, Psychological |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C098107 | flibanserin |
Not provided
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| 55-64 |
|
| 65 years and older |
|
| Male |
|
| White Hispanic |
|
| Black/African American |
|
| Black/African American Hispanic |
|
| Asian |
|
| Asian Hispanic |
|
| American Indian/Alaskan Native |
|
| Hawaiian/Pacific Islander |
|
This is the matched placebo which will be administered two tablets daily at bedtime.
Placebo: This is the matched placebo which will be administered two tablets daily at bedtime.
|
|